This hearing today has very real implications for patients everywhere. How do we ensure that drug and device companies have the right incentives to discover important new treatments for disease?

We cannot legislate scientific advances. In some areas, the lack of new treatments is attributable to a lack of scientific knowledge, not the lack of incentives.

I greatly respect and admire Ms. Brown, and I agree with her that Fast Track is an excellent program.

The foundation laid by Hatch-Waxman Act 30 years ago will continue to be the mechanism by which the management incentives development of lifesaving drugs but we do have an obligation to periodically reevaluate how the balance can be…

The loan guarantee program is important for a number of reasons. It's creating jobs, it is moving us closer to a renewable energy economy, and it represents a great opportunity to develop technologies to address the clear risks of climate…

We found no evidence of the wrongdoing to support the wild claims of House Republicans, but we ignored the big picture.

Ensuring that America generates a much larger share of its energy from clean sources should be a top priority for our Nation's energy policy.

We should focus on the success of the program and the need for clean energy financing as the threat of climate change becomes even more dire.

I yield myself 3 minutes. Mr. Chairman, the McKinley amendment provides that the Department of Defense may not make decisions based on science. Imagine, the Department of Defense should not make decisions based on science. They should…

I demand a recorded vote. The Acting CHAIR. Pursuant to clause 6 of rule XVIII, further proceedings on the amendment offered by the gentleman from West Virginia will be postponed. Amendments En Bloc No. 1 Offered by Mr. McKeon Mr. McKEON…

I believe right lines would be much better for the market and for innovation.

I commend you for tackling this issue and for seeking comment on a broad range of issues.

These claims are nonsense and contradict the express language of the statute.

The PCAST report's fourth recommendation is the creation of a new pathway that manufacturers could choose to use for initial approval of drugs shown to be safe and effective in a specific subgroup of patients.

We should create policies that foster scientific advances, but we should do so in a way that does not jeopardize public health.

I think it is important to state that the intention of the limited population pathway is to still operate within the confines of safety and efficacy, and that is not altered.

We need to ensure that patients gain access to new treatment and cures at the earliest possible time.

Federal Communications Commission had an historic week last week. You are tackling some of the most complex and pressing issues in the communications sector today.

We need new therapies to be marketed but we have got to address high prices for these therapies.

It would be an enormous setback for innovation and consumers if the incentive auction turns the wireless market into a duopoly, dominated by Verizon and AT&T.

The problem with exclusive arrangements is that they would let some companies block their competition from similar advantages.

You don't have to settle for weak open Internet rules if you exercise your full powers.

The DC Circuit Court upheld the NRC's statutory mandate to review and issue a decision on the Yucca Mountain license application.

This morning, our Nation's leading climate scientists released the country's third National Climate Assessment. The report confirms that climate change is real, is being caused by humans, and is already harming communities across America…

The Commission was right to focus on completion of the safety and evaluation report as an important and achievable milestone.